Indication

Cancer With POLE Exonucleasic Domain Mutation

1 clinical trial

1 drug

Clinical trial

Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types

Status: Completed, Estimated PCD: 2022-12-22

Drug